• Caydan Capital Partners portfolio company MitoSense signed an MOU with the University of Pittsburgh to explore joint research in space biomedicine, mitochondrial biology, and long COVID.
• Collaboration focus includes biomarker discovery, multiomics analysis, computational pipeline development, publications, and working groups tied to astronaut health and post-viral disease.
• The MOU runs for three years; any funded programs, IP terms, or commercialization plans would be set in separate definitive agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caydan Capital Partners published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.